Advanced Search
Your search returned 63 results
  • Feb 18, 2021

    Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of...

  • Oct 14, 2020

    Company Raises Revenue Growth Outlook Highlights Deep and Broad Pipeline and Technology Platforms DUBLIN, Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical...

  • Oct 6, 2020
    ELITE is the Only Study of a Rechargeable Sacral Neurostimulation System to Include All Four Indications, Including Fecal Incontinence, Which Affects Millions

    Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the InterStim™ Micro system — the only study of a...

  • Sep 25, 2020
    U.S. Patent and Trademark Office Rejects IPR Challenge to Medtronic Patent

    Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal...

  • Aug 20, 2020
    ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and Non-Obstructive Urinary Retention

    DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global,...

Show 5102550100 per page